Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 12, 2007

GlobalStem Receives Two NIH SBIR Grants

  • The NIH awarded GlobalStem two phase 1 SBIR grants. Under the first grant, the company will affiliate with a trans-NIH initiative called the Knockout Mouse Project (KOMP) to make mouse embryonic stem cell lines available for research. The second grant will help GlobalStem create genetically modified human feeder cells for the support of undifferentiated hESC.

    GlobalStem will work with NIH and other federal agencies to provide the international stem cell community with products that allow customers to conduct research with greater speed, efficiency, and confidence, notes Jonathan M. Auerbach, Ph.D., president.

    GlobalStem develops, manufactures, and distributes human and mouse stem cell research products and services. The company currently sells products in four categories: cells, media, sera, and supporting products and tools. In addition, it offers cell characterization services.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »